Coridon hits dosing milestone in herpes trial
17 October, 2013 by Dylan Bushell-EmblingThe 20 subjects enrolled in a trial of the HSV-2 vaccine under development at Allied Healthcare's (ASX:AHZ) Coridon have all received two out of three planned doses.
Technical guidelines for therapeutic services open for comment
17 October, 2013The Department of Health and Ageing has released draft technical guidelines for therapeutic services, open for consultation until 23 November 2013.
iSonea teams with uHealth for AirSonea push
16 October, 2013 by Dylan Bushell-EmblingSydney-based uHealth will work with iSonea (ASX:ISN) to pursue more sales opportunities for the latter's asthma symptom monitoring device, AirSonea.
Bioeconomy in transition
16 October, 2013 by Susan WilliamsonThis year’s AusBiotech conference will focus on the transformation of the Australian biotech industry, following its evolution and the application of its bioactivity across areas such as agriculture, food technology and health. In this preview we provide a bumper sample of what’s in store for Brisbane at the end of October.
Ellex eye treatment shows promise in early AMD
15 October, 2013 by Dylan Bushell-EmblingResults from a pilot trial of Ellex Medical Lasers' (ASX:ELX) Retinal Rejuvenation Therapy (2RT) suggest the treatment could act as an early intervention therapy for AMD.
QRxPharma expands MoxDuo deal with Aspen
15 October, 2013 by Dylan Bushell-EmblingA month after licensing MoxDuo IR for ANZ and Oceania to Aspen for $1.25m, QRxPharma (ASX:QRX) has expanded the deal to also cover South Africa.
Austrade to lead 'Australia-India Innovation in Life Sciences Roadshow'
15 October, 2013Austrade, in partnership with Australian federal and state government agencies, is organising the first Australian 'Innovation Week' in India and invites interested Australian companies to participate. While the entire program will run over three weeks, the life sciences component will run for one week, commencing 25 November 2013.
Stem sells for Regeneus
15 October, 2013 by Dylan Bushell-EmblingRegeneus, a Sydney-based company with a strong pipeline of cell-based treatments derived from adipose tissue, raised $10.5m last month in a fully subscribed IPO.
Mesoblast to buy stem cell business from Osiris
11 October, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) will pay up to US$100m to acquire the mesenchymal precursor cell business of US-based Osiris Therapeutics.
Strong results from PolyNovo's NovoSorb BTM trial
10 October, 2013 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo said its NovoSorb BTM dermal scaffold was well tolerated and effective during a 10-patient trial involving its use in free-flap donor site repair.
AusBiotech Annual Report 2013 shows year of solid delivery
10 October, 2013The AusBiotech Annual Report 2013 has been released, detailing another solid performance for AusBiotech and showing how it has delivered for its members and the Australian biotechnology industry. AusBiotech was steadfast in its advocacy and active in its representation and support of the industry, delivering a number of achievements in policy terms.
CSL to pay US$64m to settle class action suit
10 October, 2013 by Dylan Bushell-EmblingCSL (ASX:CSL) has negotiated a proposed settlement to a US class action antitrust lawsuit centred around the company's control of supply of plasma-derived protein therapeutics.
QRxPharma to refile MoxDuo NDA next month
09 October, 2013 by Dylan Bushell-EmblingAfter a positive meeting with the US FDA, QRxPharma (ASX:QRX) aims to resubmit its application for approval of pain drug MoxDuo in mid-November.
Eight more surgeons approved to use Allied's CardioCel in adults
08 October, 2013Eight surgeons, based at The Prince Charles Hospital in Brisbane, were today approved to use Allied Healthcare's (ASX: AHZ) CardioCel to repair and treat heart defects in adult patients under the Authorised Prescriber Scheme (APS).
Melbourne to host prestigious International Biotechnology Symposium
08 October, 2013In a major coup for the biotechnology industry and Australia, the International Biotechnology Symposium (IBS), a premier international conference in the rapidly growing field of biotechnology, is heading to Melbourne in 2016.
